Biocryst Pharmaceuticals INC Form 4 insider transactions

BioCryst Pharmaceuticals' President and CCO, Charles K Gayer, had 8,181 shares withheld by the company to cover tax obligations related to restricted stock unit vesting.

BioCryst Pharmaceuticals' Chief Legal Officer, Alane P. Barnes, reported the sale of 21,210 common shares under a pre-arranged 10b5-1 trading plan, alongside a tax-related disposition.

BioCryst Pharmaceuticals CEO Jon P. Stonehouse reported a tax-related stock transaction involving the withholding of shares to cover vesting restricted stock units.

BioCryst Pharmaceuticals' Chief Legal Officer, Alane P. Barnes, executed pre-planned sales of common stock totaling 161,680 shares following the exercise of stock options.

BioCryst Pharmaceuticals announced early termination of the HSR waiting period, moving its acquisition of Astria Therapeutics closer to a Q1 2026 close.

BIOCRYST Pharmaceuticals Director Amy McKee acquired 783 shares of common stock at $7.18 per share as part of her board compensation.

BIOCRYST PHARMACEUTICALS INC Director Steven Frank acquired 1,566 shares of common stock at $7.18 per share, opting for equity in lieu of a cash retainer.

BioCryst Pharmaceuticals Director Vincent Milano acquired 783 shares of common stock at $7.18 per share as part of his quarterly board retainer.

Machelle Sanders, a director at BioCryst Pharmaceuticals, sold 9,600 shares of common stock for $7.14 per share under a Rule 10b5-1 trading plan.

BioCryst Pharmaceuticals announces the acquisition of Astria Therapeutics, adding late-stage HAE compound navenibart to its pipeline and projecting significant revenue growth.

BioCryst Pharmaceuticals announces a proposed acquisition of Astria Therapeutics, Inc., aiming to expand its therapeutic portfolio and achieve synergies.

BioCryst Pharmaceuticals, Inc. announced its intent to acquire Astria Therapeutics, Inc., a move communicated to employees on October 14, 2025.

BioCryst Pharmaceuticals will acquire Astria Therapeutics for approximately $920 million in equity value, adding a late-stage HAE treatment and strengthening its rare disease pipeline.

BIOCRYST PHARMACEUTICALS Director Amy E McKee acquired 676 shares of common stock at $8.31 per share as part of her board retainer.

BioCryst Pharmaceuticals Director Steven Frank acquired 1,353 shares of common stock at $8.31 per share as part of his board retainer.

BioCryst Pharmaceuticals director Vincent Milano acquired 676 shares of common stock at $8.31 per share, opting for equity over a portion of his cash retainer.

A BioCryst Pharmaceuticals director exercised options and sold 70,000 shares of common stock for approximately $8.51 per share.

BioCryst Pharmaceuticals, Inc. has granted 147,000 restricted stock units and 305,000 employee stock options to its CFO and Head of Corporate Development, Babar Ghias, as an inducement award.

Machelle Sanders, a Director at BioCryst Pharmaceuticals, Inc., has received an automatic grant of Restricted Stock Units and stock options as part of her non-employee director compensation.

BioCryst Pharmaceuticals, Inc. Director Vincent Milano was granted 12,500 Restricted Stock Units and 27,181 stock options as part of the company's non-employee director compensation policy.

BioCryst Pharmaceuticals, Inc. director Amy McKee has received an automatic grant of Restricted Stock Units and stock options as part of the company's non-employee director compensation policy.

BioCryst Pharmaceuticals, Inc. Director Alan G. Levin was granted 12,500 Restricted Stock Units and 27,181 stock options as part of the company's non-employee director compensation policy.

BioCryst Pharmaceuticals, Inc. Director Nancy J. Hutson was granted 12,500 Restricted Stock Units and 27,181 stock options as part of the company's non-employee director compensation policy.

BioCryst Pharmaceuticals Director Theresa Heggie was granted 12,500 Restricted Stock Units and 27,181 stock options as part of her compensation, as detailed in a recent SEC Form 4 filing.

BioCryst Pharmaceuticals, Inc. Director Steven Galson reported the acquisition of 12,500 Restricted Stock Units and 27,181 stock options, alongside previous transfers of 23,940 shares to a living trust.

BioCryst Pharmaceuticals, Inc. Director Steven Frank was granted 12,500 Restricted Stock Units and 27,181 stock options as part of the company's non-employee director compensation policy.

BioCryst Pharmaceuticals Director Steven Frank acquired 333 shares of common stock on May 30, 2025, as part of his board member compensation.

BioCryst Pharmaceuticals Inc. Director Vincent Milano acquired 523 shares of common stock at $10.75 per share on May 30, 2025, as partial payment for his quarterly board retainer.

Director Steven Frank acquired shares and options in BioCryst Pharmaceuticals through automatic non-employee director grants.

Helen M. Thackray, Chief R&D Officer of BioCryst Pharmaceuticals, reports the withholding of 7,525 common stock shares to cover tax obligations related to vesting Restricted Stock Units on March 31, 2025.